OncoMatch/Clinical Trials/NCT07104331
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Is NCT07104331 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies nab-Sirolimus for epithelioid hemangioendothelioma (ehe).
Treatment: nab-Sirolimus — This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-sirolimus in patients with EHE who require systemic treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Platelets >75,000μl; ANC >1500μl; Hgb >9g/dl
Kidney function
Creatinine <1.5 x ULN or measured CrCl of >30ml/m2/1.73 m2
Liver function
Total bilirubin <2 x ULN; AST/ALT <3 x ULN
Platelets >75,000μl; ANC >1500μl; Hgb >9g/dl; Creatinine <1.5 x ULN or measured CrCl of >30ml/m2/1.73 m2; Total bilirubin <2 x ULN; AST/ALT <3 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Stanford, California
- University of Colorado · Aurora, Colorado
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Washington University St. Louis · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07104331 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify